OncoMatch/Clinical Trials/NCT06750419
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
Is NCT06750419 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies 89Zr-TLX250 PET/CT for clear cell renal cell carcinoma.
Treatment: 89Zr-TLX250 PET/CT — 89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma, and this Phase 3 bridging study in mainland Chinese patients is intended to support the successful ZIRCON data (ZIRCON Clinicaltrial.gov ID: NCT03849118)
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Prior therapy
Cannot have received: chemotherapy
Chemotherapy ... within 4 weeks prior to the planned administration of 89Zr -TLX250 or continuing adverse effects (> grade 1) from such therapy
Cannot have received: radiotherapy
Radiotherapy ... within 4 weeks prior to the planned administration of 89Zr -TLX250 or continuing adverse effects (> grade 1) from such therapy
Cannot have received: targeted therapy
Targeted therapy ... within 4 weeks prior to the planned administration of 89Zr -TLX250 or continuing adverse effects (> grade 1) from such therapy
Cannot have received: immunotherapy
Immunotherapy ... within 4 weeks prior to the planned administration of 89Zr -TLX250 or continuing adverse effects (> grade 1) from such therapy
Cannot have received: murine or chimeric antibody
Exposure to murine or chimeric antibodies within the last 5 years
Cannot have received: radionuclide
Previous administration of any radionuclide within 10 half-lives of the same
Cannot have received: experimental diagnostic or therapeutic drug
Exposure to any experimental diagnostic or therapeutic drug within 4 weeks or 5 half-lives (whichever is longer) from the date of planned administration of 89Zr-TLX250
Lab requirements
Kidney function
glomerular filtration rate (gfr) > 45 ml/min/1.73 m²
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify